RxDoctor Payments Data

Bradley Wisler, MD

Interventional Pain Medicine · Cedar Park, TXNPI 1043573892

Payments from drug & device makers

$10,650in general payments, 2019–2025

Across 383 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Protega Pharmaceutials Inc$286
  • Collegium Pharmaceutical, Inc.$254
  • Nalu Medical, Inc.$172
  • Biohaven Pharmaceutical Holding Company Ltd.$156
  • Vertiflex, Inc.$146
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$1,04110%
  • Food & beverage$9,60990%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,650 in reported general payments places this provider in the 55th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$225,835
Medicare patients
349
Services billed
2,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate101$50,478
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,183$33,652
Aimovig AutoinjectorErenumab-Aooe11$10,345
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen377$9,946
OxycontinOxycodone Hcl21$9,093
Morphine Sulfate ErMorphine Sulfate303$8,489
Hysingla ErHydrocodone Bitartrate13$6,598
Oxycodone Hcl397$5,773
Celecoxib25$1,472
Morphine Sulfate50$1,470
Gabapentin119$1,405
Diclofenac Sodium22$1,216
Fentanyl16$1,200
Naloxone Hcl15$1,089
Methadone Hcl63$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$254$50,478101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →